Naptumomab estafenatox/Durvalumab

N/A

Report date: 2024/08/06 11:09:30

Base Information

Drug NameNaptumomab estafenatox/Durvalumab
Drug Alias NameNTX-352
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocytes stimulantsTrophoblast glycoprotein modulatorsProgrammed death-ligand 1 blockers
TargetsTrophoblast glycoproteinProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Naptumomab estafenatoxDurvalumab
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeotx Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeotx Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A